CTEPH
Conditions
Interventions
Right heart catheterization on the day before BPA treatment and 3 months after BPA treatment, except at the time of blood sampling, which is usually performed in clinical practice. During hospitalizat
Sponsors
Tatsuguchi Mariko
Eligibility
Sex/Gender
All
Inclusion criteria
Inclusion criteria: Patients who meet all of the following criteria are included. 1. Patients aged 20 to 80 2. Patients diagnosed with CTEPH 3.Patients who are planning to undergo BPA and are taking the therapeutic drug riociguat 4. Persons who have obtained consent for this research by signing the consent form
Exclusion criteria
Exclusion criteria: Patients who fall under any of the following will not be included in this study. 1. Persons with serious liver disease 2. Persons with serious kidney disease 3. Women who are pregnant or may become pregnant 4. Lactating women 5. Other persons who are judged to be inappropriate by the principal investigator and the coordinator
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Area under the time curve (AUC) of Riociguat before and after BPA | — |
Secondary
| Measure | Time frame |
|---|---|
| Pharmacokinetic parameters of riociguat before and after BPA (Cmax, Tmax, elimination half-life, trough blood concentration) Lung clearance, adverse events, AUC and pharmacokinetic parameters, influence factor analysis on lung clearance | — |
Contacts
Public ContactMariko Tatsuguchi
Hamamatsu University School of Medicine
Outcome results
None listed